Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.
about
Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studiesDipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studiesStrategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the DiseaseAlogliptin benzoate for management of type 2 diabetesDipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trialsConsensus report: the current role of self-monitoring of blood glucose in non-insulin-treated type 2 diabetesDipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonAlogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus.Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials.Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats.Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease.Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptinDipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy.The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.Alogliptin (nesina) for adults with type-2 diabetes.Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches: a European expert recommendation.Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.Once weekly exenatide: efficacy, tolerability and place in therapy.Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.Alogliptin.Alogliptin: safety, efficacy, and clinical implications.Alogliptin benzoate for the treatment of type 2 diabetes.Evidence-based practice use of incretin-based therapy in the natural history of diabetes.Pharmacologic treatment of type 2 diabetes: oral medications.Combination therapy when metformin is not an option for type 2 diabetes.Alogliptin: a review of its use in patients with type 2 diabetes mellitus.Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes.Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes.NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis.The power of two: an update on fixed-dose combinations for type 2 diabetes.What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?
P2860
Q24288949-33FCA1EE-155F-4D08-9824-7D8A0D872A24Q26765047-85DE134D-5197-4D07-94AC-1EE22DAAC03CQ28069065-75F33FF8-2F1D-4525-B972-E606AA6788D8Q28083933-E6A41E7D-F207-40C0-93F3-092A8A605FC1Q28294225-6D95AE27-483F-4E41-8951-55D4D53C011DQ28732681-FBA2E2D2-0A92-4DFB-A6B2-BFE14CE593E0Q30846870-DC8CA532-F916-4786-B677-AC75C53B8574Q33785197-323BD367-3191-42DC-B46B-F7378CFF725EQ33874654-82977026-EC2F-4FB7-9F2A-E0BB3F515BFFQ35236019-19E6EB20-2CEE-4F5A-92F4-CDB3699740B5Q35688028-887743A7-29A6-42E3-A90B-76A00CD1356AQ35717211-5AF23713-1D9E-49AF-9C3A-722767BAFA8AQ36706802-D390B3A5-5004-4761-99B9-40A682C17AAEQ37195882-A4EB99EF-FE22-4EE4-8A4D-B39832F0DFDAQ37343916-6A02A869-D1B9-4BF8-89CC-DF6FD8B91A66Q37639487-E26907A4-3376-41A1-ABE3-B4732E21361DQ37733244-C70284EB-F3BB-4135-A295-2FAFAAF98932Q37866299-A23AC1D9-3457-454E-B0E3-195FAA03B408Q37910902-2E32ABEB-1C09-4DBD-BB7A-029ADCB8AA19Q38024383-1DBBD5FE-BE99-4FE1-9167-F149D7994BEFQ38058568-08937631-9D43-4D67-A033-B14870DF732FQ38076330-AEA7749F-988C-4A71-95FE-7F98453634ACQ38083112-4FD5FA2A-3E7C-4CE0-99E4-EE6CFB8A456AQ38167010-0AA424DB-1D0E-40CB-9208-0F635C3CA4E7Q38178240-72CB0D57-3B56-4C52-832D-21FD860B36D2Q38188548-9B7C4069-1043-4736-B973-71F2E69D35D7Q38197275-FCDE4143-E259-4BFD-8BC0-122A32E83A87Q38219482-71E0A0E0-73B2-4D58-A034-693F4CB3F63CQ38350347-63B15D69-AD7E-466F-9C4D-9A93624A5B8FQ38377267-39EEB602-98CC-4449-B4A5-93843DFF8752Q38412153-C7866102-2D50-4F72-8994-71803104561AQ38455771-5A577629-2BEB-426E-AC0D-1EDCD3998E27Q38468017-7EAF50C5-8DEB-4343-BAE6-9D632F6998C1Q38546981-ED0E4947-D34F-4760-AD6A-D0B1746A0822Q38556037-C9086242-C003-498A-8AD4-E8A4D2FBEF27Q38603506-BBAB6E72-D141-47F6-9212-EF14695A9F4EQ38762377-0640E838-2913-4CC1-8007-F884B3FF51F1Q38778476-70053EDB-AC28-43FA-92B5-5991274331ABQ38920983-096C50DD-B5C1-4820-A5CE-E5BEEBE302F2Q38931845-41BFCE8D-7BA8-4E22-9199-F85ED4DB3DEC
P2860
Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Initial combination therapy wi ...... patients with type 2 diabetes.
@ast
Initial combination therapy wi ...... patients with type 2 diabetes.
@en
Initial combination therapy wi ...... patients with type 2 diabetes.
@nl
type
label
Initial combination therapy wi ...... patients with type 2 diabetes.
@ast
Initial combination therapy wi ...... patients with type 2 diabetes.
@en
Initial combination therapy wi ...... patients with type 2 diabetes.
@nl
prefLabel
Initial combination therapy wi ...... patients with type 2 diabetes.
@ast
Initial combination therapy wi ...... patients with type 2 diabetes.
@en
Initial combination therapy wi ...... patients with type 2 diabetes.
@nl
P2093
P2860
P356
P1433
P1476
Initial combination therapy wi ...... patients with type 2 diabetes.
@en
P2093
Craig A Wilson
Jochen Seufert
Penny R Fleck
Qais Mekki
Silvio E Inzucchi
P2860
P304
P356
10.2337/DC10-0159
P407
P577
2010-08-19T00:00:00Z